IP Library Granted Patent US 8,771,668
Granted Patent B2
US 8,771,668 · App. 12/937,176 · Granted Jul 8, 2014

Commensal bacteria as signal mediators within a mammalian host

Inventors: John C. March (Ithaca, NY); Franklin Faping Duan (Ithaca, NY)
Assignee: Cornell University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,771,668
App. No.
12/937,176
Granted
Jul 8, 2014
Kind
B2
Abstract

Genetically engineered cells and microorganisms are provided for preventing or ameliorating diseases through genetically engineered quorum signaling. Therapeutic methods for using the cells and microorganisms to prevent or ameliorate diseases are also provided. The genetically engineered cells or microorganisms can be engineered to express a signal and used to interrupt the signaling-dependent virulence of an invading pathogen. The cells or microorganisms can be used to provide signal-dependent expression of a desirable gene in order to interrupt, prevent, and/or ameliorate a disease of mammals, such as parasitic diseases, infectious diseases, autoimmune diseases and genetic disorders.

Claims (12)

1. A method treating diabetes in a mammalian host comprising:

administering to the gastrointestinal tract of mammalian host a recombinant enteric commensal bacterium comprising a recombinant nucleic acid molecule encoding a signal that comprises a glucagon-like peptide 1 (Glp-1),

wherein the signal is expressed by the recombinant enteric commensal bacterium in the gastrointestinal tract and secreted into the gastrointestinal tract of the mammalian host by the recombinant enteric commensal bacterium in the gastrointestinal tract of the mammalian host, and the signal stimulates expression of insulin by the mammalian host to treat said diabetes.

2. The method of claim 1 wherein the commensal bacteria comprises a strain of Escherichia coli.

3. The method of claim 2 wherein the strain of Escherichia coli comprises Escherichia coli Nissle 1917.

4. The method of claim 1 wherein the diabetes is Type I diabetes.

5. A method of treating diabetes in a human, the method comprising:

administering to the gastrointestinal tract of the human a recombinant enteric commensal bacterium that comprises a recombinant nucleic acid molecule that encodes a signal that comprises glucagon-like peptide 1 (Glp-1),

wherein the signal is expressed and secreted by the enteric commensal bacterium in the gastrointestinal tract of the human host, and the signal stimulates production of insulin by the human to treat said diabetes.

6. The method of claim 5 wherein the commensal bacteria comprises a strain of Escherichia coli.

7. The method of claim 6 wherein the strain of Escherichia coli comprises Escherichia coli Nissle 1917.

8. The method of claim 5 wherein the diabetes is Type I diabetes.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2012
From: MARCH, JOHN C.; DUAN, FAPING
To: CORNELL UNIVERSITY
Reel/Frame 028419/0434 →
Continuity (2)
Provisional Application 61043426 · Apr 9, 2008
Related Publication 20110280835A1 · Nov 17, 2011